Active Share (vs S&P 500): 96.6%
· vs QQQ: 99.7%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-4.9%
· vs SPY
-7.0%
· Prev Value $1.14B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
+2.3%
· vs SPY
+0.2%
· Latest Value $978.49M
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, PFM Health Sciences, LP disclosed 81 equity positions with a combined reported value of $978.49M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 35.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were ASND ($52.14M), AXSM ($40.95M), XBI ($38.55M). By sector, the heaviest allocations are Health Care 82.7%, Industrials 6.2%. Versus the prior quarter, allocation shifted toward Other (+8.2pp), Technology (+2.2pp) and away from Consumer Staples (-1.2pp), Health Care (-10.2pp).
Versus the prior quarter, PFM Health Sciences, LP opened 24 new positions, trimmed 28 and fully exited 39, a turnover rate of 75.8% of positions. The portfolio's overlap with the prior quarter was 48% of names.
The largest new positions opened in Q3 2026 were XBI ($38.55M), SPY ($24.73M), CNMD ($14.99M).
Of the 39 positions fully exited versus the prior quarter, the largest were PEN ($19.01M), SYK ($17.83M), MTD ($17.05M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest PFM Health Sciences, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
PFM Health Sciences, LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 96 US equity positions with a combined value of $1.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Regulatory AUM (Form ADV): $1.27B as of 2026-03-31
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 4 private funds, of which 2 hedge funds
Website: pfmhealthsciences.com
Portfolio Structure
96 positions · $1.14B reported value (Q2 2026)
Top 10 holdings = 34.6% of reported value
Largest position: ASND (ASCENDIS PHARMA A/S) at 5.4%
Average position size: $11.89M
Sector Tilt
Health Care 92.9%
Industrials 5.1%
Consumer Staples 1.2%
(classified holdings cover 100% of value)
Quarterly Activity
Q2 2026: 32 new, 24 added, 40 reduced, 14 exited
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund shows a cautious but opportunistic stance, reducing exposure to large-cap pharma (ASND, LLY, NBIX) while adding mid/small-cap biotech (AXSM, UTHR, THC, INBX, INDV) and diversifying into passive ETFs (XBI, SPY), suggesting a tilt toward higher-beta, innovation-driven healthcare plays with some market-hedging.
2. Key moves:
- Added: UTHR (+38.5% shares), INDV (+84.9% shares), AXSM (+1.1% shares), THC (+0.6% shares), INBX (+3.9% shares).
- Reduced: ASND (-1.8% shares), LLY (-36.1% shares), NBIX (-4.3% shares).
- New: XBI (biotech ETF), SPY (S&P 500 ETF).
3. Portfolio structure: Active sector focus (Health Care >90%), with moderate risk appetite (mix of established pharma and high-growth biotech). Passive ETFs (XBI, SPY) provide diversification.
4. Per-holding one-liner:
- ASND: Unverified (likely biotech/pharma).
- AXSM: Unverified (likely biotech).
- XBI: Biotech ETF benchmark.
- UTHR: Unverified (likely biotech/pharma).
- THC: Hospital operator.
- INBX: Unverified (likely biotech).
- LLY: Large-cap pharma.
- NBIX: Unverified (likely biotech).
- INDV: Unverified (likely biotech/pharma).
- SPY: S&P 500 ETF benchmark.
5. Style summary: Rotating from large-cap pharma to high-growth biotech/healthcare, with selective passive hedging.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:45
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2023-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
This portfolio is broadly diversified (Top-10 = 46.1% of reported value), so a
Top-10 proxy cannot represent the whole fund — only the full-holdings reconstruction is shown.
Why there is no forecast NAV
Not published because:
Top-10 covers < 85% of reported value · Holdings-forecast backtest F1 < 0.80 · Top-10 quarterly turnover > 20%
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 60%R 60%F1 60%(modelled on 2026-Q2; 6/10 hit)
Low-confidence forecast
This fund replaces about 36% of its Top-10 each quarter and
backtests at F1 64% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-13.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-13, and will update as prices arrive.
Portfolio return+6.87%Buy & hold
QQQ synthetic benchmark-13.72%Liquidity weighted
Excess return+20.58%vs benchmark
Barra annualised vol18.3%Model estimate
Realised vol19.1%Annualised in window
Weighted beta0.64Raw exposure
Factor / specific risk75% / 25%Share of variance
Top-10 concentration68.5%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
+6.87%
Disclosed long book
QQQ synthetic benchmark
-13.72%
Liquidity-weighted constituents
Model universe, equal weight
+0.30%
Opportunity-cost reference
Excess return
+20.58%
Portfolio − benchmark
Arithmetic return sum
+6.87%
Difference vs compounded is the cross term
Weighted raw beta
0.64
Weighted holding betas
Realised volatility (annualised)
19.07%
Daily returns in window
Barra model volatility (annualised)
18.28%
Factor + specific
Factor share of variance
74.6%
Barra factors
Specific share of variance
25.4%
Stock residuals
Reported value
$339.3M
13F long US equity
2. Return attribution
The +6.87% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+1.90%
27.7%
Momentum & Growth
3
-1.55%
-22.5%
Volatility & Tail Risk
7
+5.47%
79.5%
Industry
12
+7.40%
107.7%
Specific
1
-6.35%
-92.5%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Health Care
Industry
+0.73
+8.12%
+5.90%
85.8%
Historical Volatility
Style
-0.32
-12.86%
+4.15%
60.4%
Kurtosis
Style
+0.39
+6.97%
+2.70%
39.3%
Residual Volatility
Style
+0.75
+2.66%
+1.99%
29.0%
Turnover
Style
-0.40
-4.77%
+1.93%
28.1%
Other
Industry
+0.12
+10.06%
+1.19%
17.3%
Leverage (Downside Vol)
Style
-0.41
-1.82%
+0.76%
11.0%
Non-linear Size
Style
+0.65
+0.91%
+0.59%
8.6%
Growth
Style
+0.21
+1.57%
+0.33%
4.8%
Industrials
Industry
+0.16
+2.04%
+0.32%
4.6%
Size
Style
-0.05
-1.83%
+0.09%
1.2%
Short-term Reversal
Style
-0.13
+0.79%
-0.10%
-1.4%
Max Drawdown
Style
+0.08
-1.96%
-0.16%
-2.3%
Amihud Illiquidity
Style
+0.57
-0.40%
-0.23%
-3.3%
Mid Cap
Style
+0.28
-1.69%
-0.48%
-7.0%
Beta
Style
-0.23
+4.85%
-1.13%
-16.4%
Momentum
Style
+0.53
-3.34%
-1.78%
-25.9%
Skewness
Style
+0.67
-4.21%
-2.84%
-41.3%
Specific
Specific
—
—
-6.35%
-92.5%
3. Risk attribution
Annualised volatility is 18.28%; factor risk explains 74.6% of variance and specific risk 25.4%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Health Care
Industry
+0.73
44.6%
+8.15%
8.2%
Specific
Specific
—
25.4%
+4.65%
4.7%
Other
Industry
+0.12
8.7%
+1.58%
1.6%
Momentum
Style
+0.53
7.9%
+1.45%
1.4%
Industrials
Industry
+0.16
5.7%
+1.05%
1.1%
Historical Volatility
Style
-0.32
3.0%
+0.55%
0.6%
Residual Volatility
Style
+0.75
2.1%
+0.39%
0.4%
Kurtosis
Style
+0.39
2.0%
+0.37%
0.4%
Skewness
Style
+0.67
1.7%
+0.31%
0.3%
Leverage (Downside Vol)
Style
-0.41
1.5%
+0.27%
0.3%
Mid Cap
Style
+0.28
0.9%
+0.17%
0.2%
Growth
Style
+0.21
0.8%
+0.15%
0.1%
Amihud Illiquidity
Style
+0.57
0.7%
+0.14%
0.1%
Turnover
Style
-0.40
0.3%
+0.06%
0.1%
Size
Style
-0.05
0.3%
+0.05%
0.1%
Short-term Reversal
Style
-0.13
-0.5%
-0.09%
-0.1%
Max Drawdown
Style
+0.08
-0.7%
-0.13%
-0.1%
Non-linear Size
Style
+0.65
-1.3%
-0.24%
-0.2%
Beta
Style
-0.23
-3.4%
-0.62%
-0.6%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-0.05
+2.10
-2.15
Non-linear Size
+0.65
+1.68
-1.03
Mid Cap
+0.28
+0.13
+0.16
Beta
-0.23
+1.29
-1.53
Momentum
+0.53
+0.72
-0.18
Short-term Reversal
-0.13
-0.64
+0.52
Residual Volatility
+0.75
-0.40
+1.15
Historical Volatility
-0.32
+0.86
-1.18
Liquidity
+0.03
+0.11
-0.09
Amihud Illiquidity
+0.56
+1.16
-0.59
Turnover
-0.41
+0.21
-0.61
Growth
+0.21
+0.58
-0.37
Leverage (Downside Vol)
-0.41
+0.14
-0.56
Skewness
+0.67
+0.24
+0.44
Kurtosis
+0.39
+0.21
+0.17
Max Drawdown
+0.08
-0.08
+0.17
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-19.18%
+4.32%
+14.12%
-14.12%
+14.12%
Health Care
72.6%
1.7%
+8.61%
+9.16%
+15.93%
-0.01%
-0.39%
+6.10%
Communication Services
0.0%
2.6%
+0.00%
-15.54%
+0.06%
+0.41%
-0.41%
+0.41%
Other
11.8%
0.0%
+1.91%
+0.00%
+1.57%
+0.00%
+0.23%
+0.23%
Utilities
0.0%
0.8%
+0.00%
+11.58%
-0.20%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.58%
-0.24%
-0.13%
+0.13%
-0.13%
Industrials
15.6%
11.1%
+3.01%
+7.16%
+0.91%
-0.46%
-0.19%
-0.33%
Consumer Discretionary
0.0%
8.8%
+0.00%
+5.56%
-1.66%
-0.49%
+0.49%
-0.49%
Total
+20.59%
+13.31%
-14.13%
+19.77%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
UTHR
UNITED THERAPEUTICS CORP DEL
Health Care
11.06%
+9.09%
+1.01%
Add
LLY
ELI LILLY & CO
Health Care
8.55%
+24.75%
+2.12%
Reduce
SPY
STATE STR SPDR S&P 500 ETF T
Other
7.29%
+2.16%
+0.16%
New
BBIO
BRIDGEBIO PHARMA INC
Health Care
7.09%
+19.00%
+1.35%
Add
TMO
THERMO FISHER SCIENTIFIC INC
Industrials
6.36%
+3.73%
+0.24%
Add
RVMD
REVOLUTION MEDICINES INC
Health Care
6.18%
-16.06%
-0.99%
Reduce
HUM
HUMANA INC
Health Care
5.74%
+17.93%
+1.03%
Reduce
WAT
WATERS CORP
Industrials
5.69%
+4.75%
+0.27%
Reduce
UNH
UNITEDHEALTH GROUP INC
Health Care
5.37%
+11.00%
+0.59%
Reduce
ABT
ABBOTT LABORATORIES
Health Care
5.14%
+9.80%
+0.50%
Add
MDGL
MADRIGAL PHARMACEUTICALS INC
Health Care
4.29%
-15.19%
-0.65%
Reduce
IWM
ISHARES TR
Other
3.71%
+1.24%
+0.05%
New
EXEL
EXELIXIS INC
Health Care
3.25%
+18.13%
+0.59%
New
CNC
CENTENE CORP DEL
Health Care
3.10%
+14.73%
+0.46%
Add
DHR
DANAHER CORP DEL
Industrials
2.98%
+5.18%
+0.15%
New
ICLR
ICON PUB LTD CO
Health Care
2.52%
+14.51%
+0.36%
Reduce
GH
GUARDANT HEALTH INC
Health Care
2.23%
-14.95%
-0.33%
Add
WST
WEST PHARMACEUTICAL SVSC INC
Health Care
1.78%
+12.31%
+0.22%
Reduce
GEHC
GE HEALTHCARE TECHNOLOGIES I
Health Care
1.61%
+27.00%
+0.43%
New
HCA
HCA HEALTHCARE INC
Health Care
1.22%
+16.95%
+0.21%
Add
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
LLY
Health Care
8.55%
+24.75%
+2.12%
2
BBIO
Health Care
7.09%
+19.00%
+1.35%
3
HUM
Health Care
5.74%
+17.93%
+1.03%
4
UTHR
Health Care
11.06%
+9.09%
+1.01%
5
UNH
Health Care
5.37%
+11.00%
+0.59%
6
EXEL
Health Care
3.25%
+18.13%
+0.59%
7
ABT
Health Care
5.14%
+9.80%
+0.50%
8
CNC
Health Care
3.10%
+14.73%
+0.46%
9
GPCR
Health Care
0.61%
-36.04%
-0.22%
10
GH
Health Care
2.23%
-14.95%
-0.33%
11
TWST
Health Care
0.86%
-42.25%
-0.36%
12
MDGL
Health Care
4.29%
-15.19%
-0.65%
13
RVMD
Health Care
6.18%
-16.06%
-0.99%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-13 (32 trading days), the reported portfolio returned +6.87%, versus -13.72% for the QQQ synthetic benchmark — an excess of +20.58%.
Return attribution: the largest positive style/industry contributions came from Health Care +5.90%, Historical Volatility +4.15%, Kurtosis +2.70%; the largest drags came from Skewness -2.84%, Momentum -1.78%, Beta -1.13%. Specific (stock-level) return contributed -6.35%.
Risk attribution: Barra model volatility is 18.28% annualised; factor risk explains 75% of variance and specific risk 25%. The largest factor risk sources are Health Care 44.6%, Other 8.7%, Momentum 7.9%.
Style tilt: size -0.05, momentum +0.53, volatility -0.32, liquidity +0.03; the weighted raw beta is 0.64. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+70.9 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +20.59%, selection +13.31% and interaction -14.13%.
Concentration: the top-10 positions are 68.5% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did PFM Health Sciences, LP buy in 2026-Q3?
In its 2026-Q3 13F filing, PFM Health Sciences, LP reported 81 equity positions worth $978.49M in aggregate; its largest disclosed positions were ASND ($52.14M), AXSM ($40.95M), XBI ($38.55M).
How large is PFM Health Sciences, LP's portfolio?
PFM Health Sciences, LP reported $978.49M of long equity holdings across 81 positions as of 2026-Q3. Top-10 holdings account for 35.1% of reported value.
What is PFM Health Sciences, LP's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/pfm-health-sciences/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>